Document:

Exhibit 10.74

 EXHIBIT 10.74 
  
 MORGAN STANLEY & CO. INCORPORATED 
 UBS SECURITIES LLC 
 NEEDHAM & COMPANY, LLC 
  
 $200,000,000 AGGREGATE PRINCIPAL AMOUNT 
  
 BEARINGPOINT, INC. 
  
 5.00% CONVERTIBLE SENIOR SUBORDINATED DEBENTURES 
 DUE APRIL 15, 2025 
  
 Registration Rights Agreement 
  
 Dated April 27, 2005 

 REGISTRATION RIGHTS AGREEMENT, dated as of April 27, 2005, between BearingPoint, Inc., a Delaware
corporation (together with any successor entity, herein referred to as the “Company”) and Morgan Stanley & Co. Incorporated, UBS Securities LLC and Needham & Company, LLC as placement agents (the “Placement
Agents”) under the Placement Agency Agreement (as defined below). 
  
 Pursuant to the Placement Agency Agreement, dated as of April 21, 2005, between the Company and Morgan Stanley & Co. Incorporated, UBS Securities LLC and Needham & Company, LLC, as placement
agents (the “Placement Agency Agreement”), the Company has agreed to issue and sell to certain investors (the “Investors”) $200,000,000 aggregate principal amount of its 5.00% Convertible Senior Subordinated
Debentures due 2025 (the “Securities”). The Securities will be convertible into fully paid, nonassessable shares of common stock, par value $0.01 per share, of the Company (the “Common Stock”). The Securities will
be convertible on the terms, and subject to the conditions, set forth in the Indenture (as defined herein). 
  
 To induce certain investors (the “Investors”) to enter into the purchase agreements, dated April 21, 2005 (each, a “Purchase
Agreement” and collectively, the “Purchase Agreements”), the Company has agreed to provide the registration rights set forth in this Agreement. The execution of this Agreement is a condition to the closing under the
Placement Agency Agreement. 
  
 The Company agrees with the
Placement Agents for the benefit of the beneficial owners from time to time of the Securities and the beneficial owners from time to time of the underlying Common Stock issued upon conversion of the Securities (each of the foregoing a
“Holder” and together the “Holders”), as follows: 
  
 The parties hereby agree as follows: 
  
 1. Definitions. Capitalized terms used in this Agreement without definition shall have their respective meanings set forth in the Placement Agency Agreement. As used in this Agreement, the following capitalized terms shall
have the following meanings: 
  
 “Additional
Interest” has the meaning set forth in Section 3(b) hereof. 
  
 “Additional Interest Payment Date” means each June 15th and December 15th. 
  
 “Affiliate” of any specified person means any other person which, directly or indirectly, is in control of, is controlled by, or is under
common control with, such specified person. For purposes of this definition, control of a person means the power, direct or indirect, to direct or cause the direction of the management and policies of such person whether by contract or otherwise;
and the terms “controlling” and “controlled” have meanings correlative to the foregoing. 
  

 1 

 “Agreement” means this Registration Rights Agreement. 
  
 “Amendment Effectiveness Deadline Date” has the meaning set
forth in Section 2(e) hereof. 
  
 “Amendment Filing
Target Date” has the meaning set forth in Section 2(e) hereof. 
  
 “Business Day” has the meaning set forth in the Indenture. 
  
 “Commission” means the Securities and Exchange Commission. 
  
 “Common Stock” has the meaning set forth in the preamble hereto. 
  
 “Company” has the meaning set forth in the preamble hereto.

  
 “Effectiveness Period” has the meaning set
forth in Section 2(a)(iii) hereof. 
  
 “Effectiveness
Target Date” has the meaning set forth in Section 2(a)(ii) hereof. 
  
 “Exchange Act” means the Securities Exchange Act of 1934, as amended. 
  
 “Holder” means a Person who owns, beneficially or otherwise, Transfer Restricted Securities. 
  
 “Indemnified Holder” has the meaning set forth in
Section 6(a) hereof. 
  
 “Indenture” means
the Indenture, dated as of April 27, 2005 between the Company and The Bank of New York, as Trustee (the “Trustee”), pursuant to which the Securities are to be issued, as such Indenture is amended, modified or supplemented from
time to time in accordance with the terms thereof. 
  
 “Majority of Holders” means Holders holding over 50% of the aggregate principal amount of Securities outstanding; provided that, for the purpose of this definition, a holder of shares of Common Stock which constitute
Transfer Restricted Securities shall be deemed to hold an aggregate principal amount of Securities (in addition to the principal amount of Securities held by such holder) equal to the product of (A) the quotient of (x) the number of such
shares of Common Stock held by such holder and (y) the conversion rate (as expressed in the number of shares issuable per $1,000 principal amount of Securities) in effect at the time of the conversion of Securities into such shares of Common
Stock as determined in accordance with the Indenture and (B) $1,000. 
  

 2 

 “NASD” means the National Association of Securities Dealers, Inc. 
  
 “Notice and Questionnaire” means a written notice executed
by the respective Holder and delivered to the Company containing substantially the information called for by the Selling Securityholder Notice and Questionnaire attached as Annex A to the Final Private Placement Memorandum of the Company issued
April 21, 2005 relating to the Securities. 
  
 “Notice Holder” means on any date, any Holder that has delivered a Notice and Questionnaire to the Company on or prior to such date. 
  

“Person” means an individual, partnership, corporation, company, unincorporated organization, trust, joint venture or a government or
agency or political subdivision thereof. 
  
 “Placement
Agent” has the meaning set forth in the preamble hereto. 
  
 “Purchase Agreement” has the meaning set forth in the preamble hereto. 
  
 “Prospectus” means the prospectus included in a Shelf Registration Statement, as amended or supplemented by any prospectus supplement and
by all other amendments thereto, including post-effective amendments, and all material incorporated by reference into such prospectus. 
  
 “Record Holder” means with respect to any Additional Interest Payment Date, each Person who is a Holder on the 15th day preceding the relevant Additional Interest Payment Date. 
  
 “Registration Default” has the meaning set forth in Section 3(a) hereof. 
  
 “Securities” has the meaning set forth in the preamble
hereto. 
  
 “Securities Act” means the Securities
Act of 1933, as amended. 
  
 “Selling Holder”
means a Holder that is named as a selling holder in the Shelf Registration Statement. 
  
 “Shelf Filing Deadline” has the meaning set forth in Section 2(a)(i) hereof. 
  
 “Shelf Registration Statement” has the meaning set forth in Section 2(a)(i) hereof. 
  
 “Subsequent Shelf Registration Statement” has the meaning
set forth in Section 2(c) hereof. 
  
 “Suspension
Notice” has the meaning set forth in Section 4(c) hereof. 
  

 3 

 “Suspension Period” has the meaning set forth in Section 4(b)(i) hereof.

  
 “TIA” means the Trust Indenture Act of 1939,
as amended, and the rules and regulations of the Commission thereunder, in each case, as in effect on the date the Indenture is qualified under the TIA. 
  
 “Transfer Restricted Securities” means each Security and each share of Common Stock issued upon conversion of Security until the earlier
of: 
  
 (i) the date on which such Security or
such share of Common Stock issued upon conversion has been effectively registered under the Securities Act and disposed of in accordance with the Shelf Registration Statement; 
  
 (ii) the date on which such Security or such share of Common Stock issued upon conversion is transferred in
compliance with Rule 144 under the Securities Act or may be sold or transferred by a Person who is not an Affiliate of the Company pursuant to Rule 144(k) under the Securities Act (or any other similar provision then in effect); or 
  
 (iii) the date on which such Security or such share of
Common Stock issued upon conversion ceases to be outstanding (whether as a result of redemption, repurchase and cancellation, conversion or otherwise). 
  
 “Underwritten Registration” means a registration in which Securities of the Company are sold to an underwriter for reoffering to the
public. 
  
 Unless the context otherwise requires, the singular
includes the plural, and words in the plural include the singular. 
  
 2. Shelf Registration. 
  
 (a)
The Company shall: 
  
 (i) not later than
December 31, 2005 (the “Shelf Filing Deadline”), cause to be filed a registration statement pursuant to Rule 415 under the Securities Act (the “Shelf Registration Statement”), which Shelf Registration Statement
shall provide for resales of all Transfer Restricted Securities held by Holders that have provided the information required pursuant to the terms of Section 2(b) hereof; 
  
 (ii) use its reasonable best efforts to cause the Shelf Registration Statement to be declared effective by
the Commission not later than March 31, 2006 (the “Effectiveness Target Date”); and 
  

 4 

 (iii) use its reasonable best efforts to keep the Shelf Registration Statement
continuously effective, supplemented and amended as required by the provisions of Section 4(b) hereof to the extent necessary to ensure that (A) it is available for resales by the Holders entitled to the benefit of this Agreement and
(B) it conforms with the requirements of this Agreement and the Securities Act and the rules and regulations of the Commission promulgated thereunder as announced from time to time, for a period (the “Effectiveness Period”)
until the earliest of: 
  
 (1) the date when the
Holders (other than Holders that are Affiliates of the Company) are able to sell all Transfer Restricted Securities immediately without restriction pursuant to the provisions of Rule 144(k) under the Securities Act or any similar provision then in
effect; or 
  
 (2) the date when all of the
Transfer Restricted Securities are sold pursuant to the Shelf Registration Statement or pursuant to Rule 144 under the Securities Act or any similar provision then in effect. 
  
 (b) At the time the Shelf Registration Statement is declared effective, each Holder that became a Notice
Holder on or prior to the date eight (8) Business Days prior to such time of effectiveness shall be named as a selling securityholder in the Shelf Registration Statement and the related Prospectus in such a manner as to permit such Holder to
deliver such Prospectus to purchasers of Transfer Restricted Securities in accordance with applicable law. None of the Company’s securityholders (other than Holders) shall have the right to include any of the Company’s securities in the
Shelf Registration Statement. 
  
 (c) If the
Shelf Registration Statement or any Subsequent Shelf Registration Statement ceases to be effective for any reason at any time during the Effectiveness Period (other than because all Transfer Restricted Securities registered thereunder shall have
been resold pursuant thereto or shall have otherwise ceased to be Transfer Restricted Securities), the Company shall use its reasonable best efforts to, as promptly as is practicable, obtain the withdrawal of any order suspending the effectiveness
thereof, and in any event shall, to the extent necessary, within thirty (30) days of such cessation of effectiveness amend the Shelf Registration Statement in a manner reasonably expected to obtain the withdrawal of the order suspending the
effectiveness thereof, or file an additional Shelf Registration Statement covering all of the securities that as of the date of such filing are Transfer Restricted Securities ( a “Subsequent Shelf Registration Statement”). If a
Subsequent Shelf Registration Statement is filed, the Company shall use its reasonable best 

  

 5 

 
efforts to cause the Subsequent Shelf Registration Statement to become effective as promptly as is practicable after such filing and to keep such
Registration Statement (or subsequent Shelf Registration Statement) continuously effective until the end of the Effectiveness Period. 
  
 (d) The Company shall supplement and amend the Shelf Registration Statement if required by the rules, regulations or instructions
applicable to the registration form used by the Company for such Shelf Registration Statement, if required by the Securities Act or as reasonably requested by the Placement Agents or by the Trustee on behalf of the Holders covered by such Shelf
Registration Statement. 
  
 (e) Each Holder
agrees that if such Holder wishes to sell Transfer Restricted Securities pursuant to a Shelf Registration Statement and related Prospectus, it will do so only in accordance with this Section 2(e) and Section 4. From and after the date the
Shelf Registration Statement is declared effective the Company shall, as promptly as practicable after the date a Notice and Questionnaire is delivered, and in any event upon the later of (x) fifteen (15) Business Days after such date or
(y) fifteen (15) Business Days after the expiration of any Suspension Period in effect when the Notice and Questionnaire is delivered or put into effect within fifteen (15) Business Days of such delivery date (each such date described
in (x) and (y) above, the “Amendment Filing Target Date”): 
  
 (i) if required by applicable law, file with the SEC a post-effective amendment to the Shelf Registration Statement or prepare and, if
required by applicable law, file a supplement to the related Prospectus or a supplement or amendment to any document incorporated therein by reference or file any other required document so that the Holder delivering such Notice and Questionnaire is
named as a selling securityholder in the Shelf Registration Statement and the related Prospectus in such a manner as to permit such Holder to deliver such Prospectus to purchasers of the Transfer Restricted Securities in accordance with applicable
law and, if the Company shall file a post-effective amendment to the Shelf Registration Statement, use its reasonable best effort to cause such post-effective amendment to be declared effective under the Securities Act as promptly as is practicable,
but in any event by the date (the “Amendment Effectiveness Deadline Date”) that is forty-five (45) days after the date such post effective amendment is required by this clause to be filed; 
  
 (ii) provide such Holder copies of any documents filed
pursuant to Section 2(e)(i); and 
  

 6 

 (iii) notify such Holder as promptly as practicable after the effectiveness under the
Securities Act of any post-effective amendment filed pursuant to Section 2(e)(i); 
  
 provided that if such Notice and Questionnaire is delivered during a Suspension Period, the Company shall so inform the Holder delivering such Notice and Questionnaire and shall take the actions set forth in clauses (i),
(ii) and (iii) above upon expiration of the Suspension Period in accordance with Section 4(b). Notwithstanding anything contained herein to the contrary, (i) the Company shall be under no obligation to name any Holder that is not
a Notice Holder as a selling securityholder in any Registration Statement or related Prospectus and (ii) the Amendment Effectiveness Deadline Date shall be extended by up to ten (10) Business Days from the expiration of a Suspension Period
(and the Company shall incur no obligation to pay Additional Interest during such extension) if such Suspension Period shall be in effect on the Amendment Effectiveness Deadline Date. 
  
 3. Additional Interest. 
  
 (a) Each event referred to in the following clauses (i) through (iv) is a “Registration Default”: 

 
 (i) the Shelf Registration Statement is not filed with
the Commission prior to or on the Shelf Filing Deadline; 
  
 (ii) the Shelf Registration Statement has not been declared effective by the Commission prior to or on the Effectiveness Target Date; 
  
 (iii) except as provided in Section 4(b)(i) hereof, the Shelf Registration Statement is filed and
declared effective but, during the Effectiveness Period, shall thereafter cease to be effective or fail to be usable for its intended purpose without being succeeded within five (5) Business Days by a post-effective amendment to the Shelf
Registration Statement, a supplement to the Prospectus or a report filed with the Commission pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act that cures such failure and, in the case of a post-effective amendment, is itself
immediately declared effective; 
  
 (iv) a
post-effective amendment or a supplement to a related Prospectus required pursuant to Section 2(e) is not filed by the Amendment Filing Target Date or declared effective on or prior to the Amendment Effectiveness Deadline Date; or 

 
 (v) (A) prior to or on the 45th or 60th day, as the
case may be, of any Suspension Period, such suspension has not been terminated or (B) Suspension Periods exceed an aggregate of 90 days in any 360-day period. 
  

 7 

 For purposes of this Agreement, each Registration Default set forth above shall begin and be cured on the
dates set forth in the table below: 
  

					
	 Type of
Registration Default
by Clause

	  	 Beginning
 Date        

	  	 Cure
 Date    

	 (i)
	  	Shelf Filing Deadline	  	the date the Shelf Registration Statement is filed
			
	 (ii)
	  	Effectiveness Target Date	  	the date the Shelf Registration Statement is declared effective by the Commission
			
	 (iii)
	  	the date five (5) Business Days following the date that the Shelf Registration Statement ceases to be effective or fails to be usable	  	the date any post-effective amendment is declared effective by the Commission or any supplement to the Prospectus or report is filed that makes the Shelf Registration Statement
usable
			
	 (iv)
	  	Amendment Filing Target Date	  	the date the prospectus supplement or post-effective amendment is filed
			
	 	  	Amendment Effectiveness Deadline Date	  	the date any required post-effective amendment is declared effective by the Commission
			
	 (v)
	  	the date on which a Suspension Period, or the aggregate duration of Suspension Periods in any period, exceeds the permitted number of days	  	termination of the applicable Suspension Period

  
 (b)

  
 (A) in respect of the Securities, to each
holder of Securities, if a Registration Default occurs, other than a Registration Default relating to a failure to file or have an effective Shelf Registration Statement with respect to 

  

 8 

 
shares of Common Stock issuable upon conversion of the Securities that are Transfer Restricted Securities, the Company hereby agrees, subject to
Section 3(e) below, to pay interest (“Additional Interest”) with respect to the Securities that are Transfer Restricted Securities from and including the day following the beginning of the Registration Default to but excluding
the earlier of (1) the day on which the Registration Default has been cured and (2) the date the Shelf Registration Statement is no longer required to be kept effective, accruing at a rate (x) with respect to the first 90-day period
during which a Registration Default shall have occurred and be continuing, equal to 0.25% per annum of the principal amount of the Securities, and (y) with respect to the period commencing on the 91st day following the day the Registration
Default shall have occurred and be continuing, equal to 0.25% per annum of the principal amount of the Securities; provided that in no event shall Additional Interest accrue at a rate per year exceeding 0.24% of the principal amount of
the Securities; and 
  
 (B) in respect of any
shares of Common Stock, to each holder of shares of Common Stock issued upon conversion of the Securities, no Additional Interest on such Common Stock will be payable. 
  
 (c) All accrued Additional Interest shall be paid in arrears to Record Holders by the Company on each
Additional Interest Payment Date. Upon the cure of all Registration Defaults relating to any particular Security, the accrual of Additional Interest with respect to such Security will cease. 
  
 (d) All obligations of the Company set forth in this
Section 3 that are outstanding with respect to any Transfer Restricted Security at the time such security ceases to be a Transfer Restricted Security shall survive until such time as all such obligations with respect to such Transfer Restricted
Security shall have been satisfied in full. 
  
 (e) The obligation of the Company to pay Additional Interest pursuant to this Section 3 is subject to the subordination provisions set forth in Article 4 of the Indenture. 
  
 The Additional Interest set forth above shall be the exclusive monetary remedy available to the Holders for each
Registration Default. 
  

 9 

 4. Registration Procedures. 
  
 (a) In connection with the Shelf Registration Statement, the Company shall comply with all the provisions of
Section 4(b) hereof and shall use its reasonable best efforts to effect such registration to permit the sale of the Transfer Restricted Securities, and pursuant thereto, shall prepare and file with the Commission a Shelf Registration Statement
relating to the registration on any appropriate form under the Securities Act. 
  
 (b) In connection with the Shelf Registration Statement and any Prospectus required by this Agreement to permit the sale or resale of
Transfer Restricted Securities, the Company shall: 
  
 (i) Subject to any notice by the Company in accordance with this Section 4(b) of the existence of any fact or event of the kind described in Section 4(b)(iii)(D), use its reasonable best efforts to keep the Shelf Registration
Statement continuously effective during the Effectiveness Period; upon the occurrence of any event that would cause the Shelf Registration Statement or the Prospectus contained therein (A) to contain a material misstatement or omission or
(B) not to be effective and usable for resale of Transfer Restricted Securities during the Effectiveness Period, the Company shall file as promptly as is practicable an appropriate amendment to the Shelf Registration Statement, a supplement to
the Prospectus or a report filed with the Commission pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act, in the case of clause (A), correcting any such misstatement or omission, and, in the case of either clause (A) or (B),
use its reasonable best efforts to cause such amendment to be declared effective and the Shelf Registration Statement and the related Prospectus to become usable for their intended purposes as soon as practicable thereafter. Notwithstanding the
foregoing, the Company may suspend the effectiveness of the Shelf Registration Statement by written notice to the Holders for a period not to exceed an aggregate of 45 days in any 90-day period (each such period, a “Suspension
Period”) if: 
  
 (x) there are certain
circumstances relating to pending corporate developments, public filings with the Commission or similar events; 
  
 (y) an event occurs and is continuing as a result of which the Shelf Registration Statement, the Prospectus, any amendment or supplement
thereto, or any document incorporated by reference therein would, in the Company’s judgment, contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements
therein not misleading; and 
  

 10 

 (z) the Company determines in good faith that the disclosure of such event at such time
would be seriously detrimental to the Company and its subsidiaries; 
  
 provided that, in the event the disclosure relates to a previously undisclosed proposed or pending material business transaction, the disclosure of which the Company determines in good faith would be reasonably likely to impede the
Company’s ability to consummate such transaction, the Company may extend a Suspension Period from 45 days to 60 days; provided, however, that Suspension Periods shall not exceed an aggregate of 90 days in any 360-day period. The Company
shall not specify in the written notice to the Holders the nature of the event giving rise to the Suspension Period. 
  
 (ii) Prepare and file with the Commission such amendments and post-effective amendments to the Shelf Registration Statement as may be
necessary to keep the Shelf Registration Statement effective during the Effectiveness Period; cause the Prospectus to be supplemented by any required Prospectus supplement, and as so supplemented to be filed pursuant to Rule 424 under the Securities
Act, and to comply fully with the applicable provisions of Rules 424 and 430A under the Securities Act in a timely manner; and comply with the provisions of the Securities Act with respect to the disposition of all Securities covered by the Shelf
Registration Statement during the applicable period in accordance with the intended method or methods of distribution by the sellers thereof set forth in the Shelf Registration Statement or supplement to the Prospectus. 
  
 (iii) Advise each Selling Holder as promptly as is
practicable and, if requested by such Selling Holder, to confirm such advice in writing, except as provided in clause (D) below: 
  
 (A) when the Prospectus or any supplement to the Prospectus or post-effective amendment has been filed, and, with respect to the Shelf
Registration Statement or any post-effective amendment thereto, when the same has become effective, 
  
 (B) of any request by the Commission for amendments to the Shelf Registration Statement or amendments or supplements to the Prospectus or
for additional information relating thereto, 
  
 (C) of the issuance by the Commission of any stop order suspending the effectiveness of the Shelf Registration Statement under the Securities Act or of the suspension by 

  

 11 

 
any state securities commission of the qualification of the Transfer Restricted Securities for offering or sale in any jurisdiction, or the initiation of any
proceeding for any of the preceding purposes, or 
  
 (D) of the existence of any fact or the happening of any event, during the Effectiveness Period, that makes any statement of a material fact made in the Shelf Registration Statement, the Prospectus, any amendment or supplement thereto, or
any document incorporated by reference therein untrue, or that requires the making of any additions to or changes in the Shelf Registration Statement or the Prospectus in order to make the statements therein not misleading. 
  
 If at any time the Commission shall issue any stop order suspending the
effectiveness of the Shelf Registration Statement, or any state securities commission or other regulatory authority shall issue an order suspending the qualification or exemption from qualification of the Transfer Restricted Securities under state
securities or Blue Sky laws, the Company shall use its reasonable best efforts to obtain the withdrawal or lifting of such order at the earliest possible time and will provide to each Holder who is named in the Shelf Registration Statement notice of
the withdrawal of any such order as promptly as is practicable. 
  
 (iv) Make available at reasonable times for inspection by one or more representatives of the Selling Holders, designated in writing by a Majority of Holders whose Transfer Restricted Securities are included in the
Shelf Registration Statement, and any attorney or accountant retained by such Selling Holders, all financial and other records, pertinent corporate documents and properties of the Company as shall be reasonably necessary to enable them to conduct a
reasonable investigation within the meaning of Section 11 of the Securities Act, and cause the Company’s officers, directors, managers and employees to supply all information reasonably requested by any such representative or
representatives of the Selling Holders, attorney or accountant in connection therewith; provided, however, that the Company shall have no obligation to deliver information to any Selling Holder or representative pursuant to this
Section 4(b)(iv) unless such Selling Holder or representative shall have executed and delivered a confidentiality agreement in a form acceptable to the Company relating to such information. 
  
 (v) If requested by any Selling Holder, incorporate as
promptly as is practicable in the Shelf Registration Statement or Prospectus, pursuant to a supplement or post-effective amendment 

  

 12 

 
if necessary, such information as such Selling Holder may reasonably request relating to such Selling Holder or the plan of distribution of the Transfer
Restricted Securities. 
  
 (vi) Furnish to each
Selling Holder upon its request, without charge, at least one copy of the Shelf Registration Statement, as first filed with the Commission, and of each amendment thereto (and any exhibits thereto as such Person may request). 
  
 (vii) Deliver to each Selling Holder, without charge, as
many copies of the Prospectus (including each preliminary Prospectus) and any amendment or supplement thereto as such Persons reasonably may request; subject to any notice by the Company in accordance with this Section 4(b) of the existence of
any fact or event of the kind described in Section 4(b)(iii)(D), the Company hereby consents to the use of the Prospectus and any amendment or supplement thereto by each of the Selling Holders in connection with the offering and the sale of the
Transfer Restricted Securities covered by the Prospectus or any amendment or supplement thereto. 
  
 (viii) Before any public offering of Transfer Restricted Securities, cooperate with the Selling Holders and their counsel in connection
with the registration and qualification of the Transfer Restricted Securities under the securities or Blue Sky laws of such jurisdictions in the United States as the Selling Holders may reasonably request and do any and all other acts or things
necessary or advisable to enable the disposition in such jurisdictions of the Transfer Restricted Securities covered by the Shelf Registration Statement; provided, however, that the Company shall not be required (A) to register or
qualify as a foreign corporation or a dealer of securities where it is not now so qualified or to take any action that would subject it to the service of process in any jurisdiction where it is not now so subject or (B) to subject itself to
general or unlimited service of process or to taxation in any such jurisdiction if they are not now so subject. 
  
 (ix) Cooperate with the Selling Holders to facilitate the timely preparation and delivery of certificates representing Transfer Restricted
Securities to be sold and not bearing any restrictive legends (unless required by applicable securities laws); and enable such Transfer Restricted Securities to be in such denominations and registered in such names as the Holders may request at
least two Business Days before any sale of Transfer Restricted Securities. 
  

 13 

 (x) Use its reasonable best efforts to cause the Transfer Restricted Securities covered
by the Shelf Registration Statement to be registered with or approved by such other U.S. governmental agencies or authorities as may be necessary to enable the seller or sellers thereof to consummate the disposition of such Transfer Restricted
Securities. 
  
 (xi) Subject to
Section 4(b)(i) hereof, if any fact or event contemplated by Section 4(b)(iii)(D) hereof shall exist or have occurred, use its reasonable best efforts to prepare a supplement or post-effective amendment to the Shelf Registration Statement
or related Prospectus or any document incorporated therein by reference or file any other required document so that, as thereafter delivered to the purchasers of Transfer Restricted Securities, the Prospectus will not contain an untrue statement of
a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances in which they are made, not misleading. 
  
 (xii) Provide CUSIP numbers for all Transfer Restricted
Securities sold pursuant to the Shelf Registration Statement not later than the effective date of the Shelf Registration Statement and provide the Trustee under the Indenture with certificates for the Securities that are in a form eligible for
deposit with The Depository Trust Company. 
  
 (xiii) Cooperate and assist in any filings required to be made with the NASD and in the performance of any due diligence investigation by any underwriter that is required to be retained in accordance with the rules and regulations of the
NASD. 
  
 (xiv) Otherwise use its reasonable best
efforts to comply with all applicable rules and regulations of the Commission and all reporting requirements under the rules and regulations of the Exchange Act. 
  
 (xv) Cause the Indenture to be qualified under the TIA not later than the effective date of the Shelf
Registration Statement required by this Agreement, and, in connection therewith, cooperate with the Trustee and the holders of Securities to effect such changes to the Indenture as may be required for such Indenture to be so qualified in accordance
with the terms of the TIA; and execute and use its reasonable best efforts to cause the Trustee thereunder to execute all documents that may be required to effect such changes and all other forms and documents required to be filed with the
Commission to enable such Indenture to be so qualified in a timely manner. 
  

 14 

 (xvi) Cause all Common Stock covered by the Shelf Registration Statement to be listed or
quoted, as the case may be, on each securities exchange or automated quotation system on which Common Stock is then listed or quoted. For the avoidance of doubt, the Shelf Registration Statement shall cover a number of shares of Common Stock equal
to the full number of shares of Common Stock into which the Securities would be convertible assuming the Company does not elect to deliver cash in lieu of shares of Common Stock upon conversion of the Securities. 
  
 (xvii) Provide to each Holder upon written request each
document filed with the Commission pursuant to the requirements of Section 13 and Section 15 of the Exchange Act after the effective date of the Shelf Registration Statement, unless such document is available through the Commission’s
EDGAR system. 
  
 (xviii) Subject to
Section 4(b)(i) hereof, take all other actions reasonably necessary in order to expedite or facilitate the disposition of Transfer Restricted Securities. 
  

(c) Each Holder agrees by acquisition of a Transfer Restricted Security that, upon receipt of any notice (a “Suspension
Notice”) from the Company of the existence of any fact of the kind described in Section 4(b)(iii)(D) hereof, such Holder will forthwith discontinue disposition of Transfer Restricted Securities pursuant to the Shelf Registration
Statement until: 
  
 (i) such Holder has received
copies of the supplemented or amended Prospectus contemplated by Section 4(b)(xi) hereof; or 
  
 (ii) such Holder is advised in writing by the Company that the use of the Prospectus may be resumed, and has received copies of any
additional or supplemental filings that are incorporated by reference in the Prospectus. 
  
 If so directed by the Company, each Holder will deliver to the Company (at the Company’s expense) all copies, other than permanent file copies then in such Holder’s possession, of the Prospectus covering
such Transfer Restricted Securities that was current at the time of receipt of such Suspension Notice. 
  
 (d) Each Holder agrees by acquisition of a Transfer Restricted Security, that no Holder shall be entitled to sell any of such Transfer
Restricted Securities pursuant to a Registration Statement, or to receive a Prospectus relating thereto, unless such Holder has furnished the Company with a Notice and Questionnaire as required pursuant to Section 2(b) or 2(e), as the case may
be, hereof (including the information required to be included in such Notice and Questionnaire) and the information set forth 

  

 15 

 
in the next sentence. Each Notice Holder agrees promptly to furnish to the Company all information required to be disclosed in order to make the information
previously furnished to the Company by such Notice Holder not misleading and any other information regarding such Notice Holder and the distribution of such Transfer Restricted Securities as the Company may from time to time reasonably request in
writing. Any sale of any Transfer Restricted Securities by any Holder shall constitute a representation and warranty by such Holder that the information relating to such Holder and its plan of distribution is as set forth in the Prospectus delivered
by such Holder in connection with such disposition, that such Prospectus does not as of the time of such sale contain any untrue statement of a material fact relating to or provided by such Holder to its plan of distribution and that such Prospectus
does not as of the time of such sale omit to state any material fact relating to or provided by such Holder or its plan of distribution necessary to make the statements in such Prospectus, in the light of the circumstances under which they were
made, not misleading. 
  
 (e) Each Holder agrees
by acquisition of a Transfer Restricted Security that, upon receipt of any Suspension Notice, such Holder will keep the existence of a suspension period in confidence. 
  
 5. Registration Expenses. 
  

All expenses incident to the Company’s performance of or compliance with this Agreement shall be borne by the Company regardless of whether a
Shelf Registration Statement becomes effective, including, without limitation: 
  
 (i) all registration and filing fees and expenses (including filings made with the NASD); 
  
 (ii) all fees and expenses of compliance with federal
securities and state Blue Sky or securities laws; 
  
 (iii) all expenses of printing (including printing of Prospectuses and certificates for the Common Stock to be issued upon conversion of the Securities) and the Company’s expenses for messenger and delivery services and telephone;

  
 (iv) all fees and disbursements of counsel to
the Company; 
  
 (v) all application and filing
fees in connection with listing (or authorizing for quotation) of the Common Stock on a national securities exchange or automated quotation system pursuant to the requirements hereof; and 
  
 (vi) all fees and disbursements of independent certified
public accountants of the Company. 
  

 16 

 The Company shall bear its internal expenses (including, without limitation, all salaries and expenses of
their officers and employees performing legal, accounting or other duties), the expenses of any annual audit and the fees and expenses of any Person, including special experts, retained by the Company. 
  
 All fees and expenses of the Notice Holders, including fees and expenses of
counsel, shall be borne by the Notice Holders; provided that the Company shall pay the reasonable fees and expenses of one law firm selected by the Majority of Holders to represent all Notice Holders. 
  
 6. Indemnification and Contribution. 
  
 (a) The Company agrees to indemnify and hold harmless each
Holder (including each Placement Agent), its directors, officers, and employees and each person, if any, who controls any such Holder within the meaning of the Securities Act or the Exchange Act (each, an “Indemnified Holder”),
against any loss, claim, damage, liability or expense, joint or several, or any action in respect thereof (including, but not limited to, any loss, claim, damage, liability or action relating to resales of the Transfer Restricted Securities), to
which such Indemnified Holder may become subject, insofar as any such loss, claim, damage, liability or action arises out of, or is based upon: 
  
 (i) any untrue statement or alleged untrue statement of a material fact contained in (A) the Shelf Registration Statement as
originally filed or in any amendment thereof, in any Prospectus, or in any amendment or supplement thereto or (B) any blue sky application or other document or any amendment or supplement thereto prepared or executed by the Company (or based
upon written information furnished by or on behalf of the Company expressly for use in such blue sky application or other document or amendment or supplement) filed in any jurisdiction specifically for the purpose of qualifying any or all of the
Transfer Restricted Securities under the securities law of any state or other jurisdiction; or 
  
 (ii) the omission or alleged omission to state therein any material fact required to be stated therein or necessary to make the statements
therein, in the light of the circumstances under which they were made, not misleading, 
  
 and agrees to reimburse each Indemnified Holder promptly upon demand for any legal or other expenses reasonably incurred by such Indemnified Holder in connection with investigating, defending, settling, compromising or paying any 

  

 17 

 
such loss, claim, damage, liability, expense or action; provided, however, that the Company shall not be liable in any such case to the extent that
any such loss, claim, damage, liability or expense arises out of, or is based upon, any untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with written information furnished to the
Company by or on behalf of such Holder (or its related Indemnified Holder) specifically for use therein; provided, further, that the foregoing indemnity agreement with respect to any prospectus shall not inure to the benefit of a Holder, or
any person controlling such Holder, who failed to deliver a prospectus, as then amended or supplemented, (so long as the prospectus and any amendment or supplement thereto was provided by the Company to the Holder on a timely basis prior to the sale
of Transfer Restricted Securities by such Holder pursuant to a Shelf Registration Statement to the Asserting Person, in order to permit proper delivery upon confirmation of such sale), to the person (the “Asserting Person”) asserting any
losses, claims, damages, liabilities, expenses or judgments caused by any untrue statement or alleged untrue statement of a material fact contained in any prospectus, or caused by any omission or alleged omission to state therein a material fact
required to be stated therein or necessary to make the statements therein not misleading, if such material misstatement or omission or alleged material misstatement or omission was cured in the prospectus, as so amended or supplemented. The
foregoing indemnity agreement is in addition to any liability which the Company may otherwise have. 
  
 (b) Each Holder, severally and not jointly, agrees to indemnify and hold harmless the Company, its directors, officers and employees and
each person, if any, who controls the Company within the meaning of the Securities Act or the Exchange Act to the same extent as the foregoing indemnity from the Company to each such Holder, but only with reference to written information relating to
such Holder furnished to the Company by or on behalf of such Holder specifically for inclusion in the documents referred to in the foregoing indemnity. The indemnity agreement set forth in this Section shall be in addition to any liabilities which
any such Holder may otherwise have. In no event shall any Holder, its directors, officers, employees or any person who controls such Holder be liable or responsible for any amount in excess of the amount by which the total amount received by such
Holder with respect to its sale of Transfer Restricted Securities pursuant to a Shelf Registration Statement exceeds (i) the amount paid by such Holder for such Transfer Restricted Securities and (ii) the amount of any damages that such
Holder, its directors, officers, employees or any person who controls such Holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. 
  
 (c) Promptly after receipt by an indemnified party under
this Section 6 of notice of any claim or the commencement of any action, the indemnified party shall, if a claim in respect thereof is to be made against 

  

 18 

 
the indemnifying party under this Section 6, notify the indemnifying party in writing of the claim or the commencement of that action; provided,
however, that the failure to notify the indemnifying party shall not relieve it from any liability which it may have under this Section 6 except to the extent it has been materially prejudiced by such failure and, provided, further,
that the failure to notify the indemnifying party shall not relieve it from any liability which it may have to an indemnified party otherwise than under this Section 6. If any such claim or action shall be brought against an indemnified party,
and it shall notify the indemnifying party thereof, the indemnifying party shall be entitled to participate therein and, to the extent that it wishes, jointly with any other similarly notified indemnifying party, to assume the defense thereof with
counsel satisfactory to the indemnified party. After notice from the indemnifying party to the indemnified party of its election to assume the defense of such claim or action, the indemnifying party shall not be liable to the indemnified party under
this Section 6 for any legal or other expenses subsequently incurred by the indemnified party in connection with the defense thereof other than reasonable costs of investigation; provided, however, that the Holders shall have the right
to employ a single counsel to represent jointly the Holders and their directors, officers, employees and controlling persons who may be subject to liability arising out of any claim in respect of which indemnity may be sought by the Holders against
the Company under this Section 6 if the Holders seeking indemnification shall have been advised by legal counsel that there may be one or more legal defenses available to such Holders and their respective directors, officers, employees and
controlling persons that are different from or additional to those available to the Company, and in that event, the fees and expenses of such separate counsel shall be paid by the Company. 
  
 (d) The indemnifying party under this Section 6 shall
not be liable for any settlement of any proceeding effected without its written consent, which shall not be withheld unreasonably, but if settled with such consent or if there is a final judgment for the plaintiff, the indemnifying party agrees to
indemnify the indemnified party against any loss, claim, damage, liability or expense by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to
reimburse the indemnified party for fees and expenses of counsel as contemplated by this Section 6(d) hereof, the indemnifying party agrees that it shall be liable for any settlement of any proceeding effected without its written consent if
(i) such settlement is entered into more than 30 days after receipt by such indemnifying party of the aforesaid request and (ii) such indemnifying party shall not have reimbursed the indemnified party in accordance with such request prior
to the date of such settlement. No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement, compromise or consent to the 

  

 19 

 
entry of judgment in any pending or threatened action, suit or proceeding in respect of which any indemnified party is a party and indemnity was or could
have been sought hereunder by such indemnified party, unless such settlement, compromise or consent (x) includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such action, suit or
proceeding and (y) does not include a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party. 
  

(e) If the indemnification provided for in this Section 6 shall for any reason be unavailable or insufficient to hold harmless an
indemnified party under Section 6(a) or 6(b) in respect of any loss, claim, damage or liability (or action in respect thereof) referred to therein, each indemnifying party shall, in lieu of indemnifying such indemnified party, contribute to the
amount paid or payable by such indemnified party as a result of such loss, claim, damage or liability (or action in respect thereof): 
  
 (i) in such proportion as is appropriate to reflect the relative benefits received by the Company from the offering and sale of the
Transfer Restricted Securities on the one hand and a Holder with respect to the sale by such Holder on the other hand, or 
  
 (ii) if the allocation provided by Section (6)(e)(i) is not permitted by applicable law, in such proportion as is appropriate to
reflect not only the relative benefits referred to in Section 6(e)(i) but also the relative fault of the Company on the one hand and the Holders on the other hand in connection with the statements or omissions or alleged statements or alleged
omissions that resulted in such loss, claim, damage or liability (or action in respect thereof), as well as any other relevant equitable considerations. 
  
 The relative benefits received by the Company on the one hand and a Holder on the other hand with respect to such offering and such sale shall be deemed to be in the same
proportion as the total net proceeds from the offering of the Securities purchased under the Purchase Agreements (before deducting expenses) received by the Company, on the one hand, bear to the total proceeds received by such Holder with respect to
its sale of Transfer Restricted Securities on the other hand. The relative fault of the parties shall be determined by reference to whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a
material fact relates to information supplied by the Company on the one hand or the Holders on the other hand, the intent of the parties and their relative knowledge, access to information and opportunity to correct or prevent such statement or
omission. The Company and each Holder agree that it would not be just and equitable if the amount of contribution pursuant to this Section 6(e) were determined by pro rata allocation or by any other method of allocation that does not
take into account the equitable considerations referred to in the first sentence of this Section 6(e). 
  

 20 

 The amount paid or payable by an indemnified party as a result of the loss, claim, damage or liability,
or action in respect thereof, referred to above in this Section 6 shall be deemed to include, for purposes of this Section 6, any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or
defending or preparing to defend any such action or claim. 
  
 Notwithstanding the provisions of this Section 6, no Holder shall be required to contribute any amount in excess of the amount by which the total price at which the Transfer Restricted Securities purchased by it were resold exceeds the
amount of any damages which such Holder has otherwise been required to pay by reason of any untrue or alleged untrue statement or omission or alleged omission. No Person guilty of fraudulent misrepresentation (within the meaning of
Section 11(f) of the Securities Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation. The Holders’ obligations to contribute as provided in this Section 6(e) are several and
not joint. 
  
 (f) The provisions of this
Section 6 shall remain in full force and effect, regardless of any investigation made by or on behalf of any Holder or the Company or any of the directors, officers, employees or controlling persons referred to in this Section 6, and will
survive the sale by a Holder. 
  
 7. Rule 144A and Rule 144.
The Company agrees with each Holder, for so long as any Transfer Restricted Securities remain outstanding and during any period in which the Company (i) is not subject to Section 13 or 15(d) of the Exchange Act, to make available, upon
request of any Holder, to such Holder or beneficial owner of Transfer Restricted Securities in connection with any sale thereof and any prospective purchaser of such Transfer Restricted Securities designated by such Holder or beneficial owner, the
information required by Rule 144A(d)(4) under the Securities Act in order to permit resales of such Transfer Restricted Securities pursuant to Rule 144A, and (ii) is subject to Section 13 or 15 (d) of the Exchange Act, to make all
filings required thereby in a timely manner in order to permit resales of such Transfer Restricted Securities pursuant to Rule 144. 
  
 8. No Participation in Underwritten Registrations. No Holder may participate in any Underwritten Registration hereunder without the prior consent
of the Company. 
  
 9. Miscellaneous. 
  
 (a) Remedies. The Company acknowledges and agrees
that any failure by the Company to comply with its obligations under Section 2 hereof may result in material irreparable injury to the Placement Agents or the Holders for which there is no adequate remedy at law, that it will not 

  

 21 

 
be possible to measure damages for such injuries precisely, and that, in the event of any such failure, the Placement Agents or any Holder may obtain such
relief as may be required to specifically enforce the Company’s obligations under Section 2 hereof. The Company further agrees to waive the defense in any action for specific performance that a remedy at law would be adequate. 

 
 (b) Actions Affecting Transfer Restricted
Securities. The Company shall not, directly or indirectly, take any action with respect to the Transfer Restricted Securities as a class that would adversely affect, in any material respect, the ability of the Holders to include such Transfer
Restricted Securities in a registration undertaken pursuant to this Agreement. 
  
 (c) No Inconsistent Agreements. The Company has not, as of the date hereof, entered into, nor shall it, on or after the date
hereof, enter into, any agreement with respect to its Common Stock or the Securities that is inconsistent with the rights granted to the Holders in this Agreement or otherwise conflicts with the provisions hereof. In addition, the Company shall not
grant to any of its securityholders (other than the Holders in such capacity) the right to include any of its securities in the Shelf Registration Statement provided for in this Agreement other than the Transfer Restricted Securities. 
  
 (d) Amendments and Waivers. This Agreement may not be
amended, modified or supplemented, and waivers or consents to or departures from the provisions hereof may not be given, unless the Company has obtained the written consent of a Majority of Holders; provided, however, that with respect
to any matter that directly or indirectly adversely affects the rights of any Placement Agent hereunder, the Company shall obtain the written consent of each such Placement Agent against which such amendment, qualification, supplement, waiver or
consent is to be effective. Notwithstanding the foregoing (except the foregoing proviso), a waiver or consent to depart from the provisions hereof, with respect to a matter, which relates exclusively to the rights of Holders whose securities are
being sold pursuant to a Shelf Registration Statement and does not directly or indirectly adversely affect the rights of other Holders in any material respect, may be given by the Selling Holders holding over 50% of the aggregate principal amount of
the Securities outstanding that are held by the Selling Holders. 
  
 (e) Notices. All notices and other communications provided for or permitted hereunder shall be made in writing by hand delivery, first class mail (registered or certified, return receipt requested), telex,
facsimile transmission, or air courier guaranteeing overnight delivery: 
 (e) Notices. All notices and other
communications provided for or permitted hereunder shall be made in writing by hand delivery, first class mail (registered or certified, return receipt requested), telex, facsimile transmission, or air courier guaranteeing overnight delivery:

  
 (i) if to a Holder, at the address set forth
on the records of the registrar under the Indenture or the transfer agent of the Common Stock, as the case may be; and 
  

 22 

 (ii) if to the Company, initially at its address set forth in the Placement Agency
Agreement, 
  
 With a copy to: 
  
 Fried, Frank, Harris, Shriver & Jacobson LLP

 1001 Pennsylvania Avenue, NW 
 Washington, DC 20004 
 Telephone: 202.639.7120 
 Facsimile: 202.639.7003 
 Attention: Richard A. Steinwurtzel, Esq. 
  
 All such notices and communications shall be deemed to have been duly given: at the time delivered by hand, if personally delivered; five
(5) Business Days after being deposited in the mail, postage prepaid, if mailed; when answered back, if telexed; when receipt acknowledged, if transmitted by facsimile; and on the next Business Day, if timely delivered to an air courier
guaranteeing overnight delivery. 
  
 Any party hereto may change
the address for receipt of communications by giving written notice to the others. 
  
 (f) Successors and Assigns. This Agreement shall inure to the benefit of and be binding upon the successors and assigns of each of
the parties, including without limitation and without the need for an express assignment, subsequent Holders. The Company hereby agrees to extend the benefit of this Agreement to any Holder and any such Holder may specifically enforce the provisions
of this Agreement as if an original party hereto. 
  
 (g) Counterparts. This Agreement may be executed in any number of counterparts and by the parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall
constitute one and the same agreement. 
  
 (h)
Securities Held by the Company or Its Affiliates. Whenever the consent or approval of Holders of a specified percentage of Transfer Restricted Securities is required hereunder, Transfer Restricted Securities held by the Company or its
Affiliates (other than subsequent Holders if such subsequent Holders are deemed to be Affiliates solely by reason of their holding of such Securities) shall not be counted in determining whether such consent or approval was given by the Holders of
such required percentage. 
  

 23 

 (i) Headings. The headings in this Agreement are for convenience of reference only
and shall not limit or otherwise affect the meaning hereof. 
  
 (j) Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York. 
  
 (k) Severability. If any one or more of the provisions contained herein, or the application thereof
in any circumstance, is held invalid, illegal or unenforceable, the validity, legality and enforceability of any such provision in every other respect and of the remaining provisions contained herein shall not be affected or impaired thereby, it
being intended that all of the rights and privileges of the parties shall be enforceable to the fullest extent permitted by law. 
  
 (l) Entire Agreement. This Agreement is intended by the parties as a final expression of their agreement and intended to be a
complete and exclusive statement of the agreement and understanding of the parties hereto in respect of the subject matter contained herein. There are no restrictions, promises, warranties or undertakings, other than those set forth or referred to
herein with respect to the registration rights granted by the Company with respect to the Transfer Restricted Securities. This Agreement supersedes all prior agreements and understandings between the parties with respect to such subject matter.

  

 24 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	BEARINGPOINT, INC.
		
	By:	 	 /s/ Joseph Corbett

	Name:	 	Joseph Corbett
	Title:	 	 Executive Vice President and
 Chief Financial
Officer

	
	Confirmed and accepted as of the date first above written on behalf of the Holders:
	
	MORGAN STANLEY & CO. INCORPORATED, as     Placement Agent
		
	By:	 	 /s/ Kenneth G. Putt

	Name:	 	Kenneth G. Putt
	Title:	 	Managing Director
	
	UBS SECURITIES LLC, as Placement Agent
		
	By:	 	 /s/ Brian Webber

	Name:	 	Brian Webber
	Title:	 	Managing Director
		
	By:	 	 /s/ Michael Denbeau

	Name:	 	Michael Denbeau
	Title:	 	Director
	
	NEEDHAM & COMPANY, as Placement Agent
		
	By:	 	 /s/ Warren Foss

	Name:	 	Warren Foss
	Title:	 	Chairman, Managing DirectorExhibit 10.75

 EXHIBIT 10.75 
  
 $40,000,000 AGGREGATE PRINCIPAL AMOUNT 
  
 BEARINGPOINT, INC. 
  
 0.50% CONVERTIBLE SENIOR SUBORDINATED DEBENTURES 
 DUE JULY 2010 
  
 AND 
  
 COMMON STOCK PURCHASE WARRANTS 
  
 Securities Purchase Agreement 
  
 dated July 15, 2005 

 TABLE OF CONTENTS 
  

							
	 	  	 	 	 	  	Page

	Section 1.	  	Representations, Warranties and Covenants of the Company	  	2
				
	 	  	(a)	 	No Registration	  	2
				
	 	  	(b)	 	No Integration	  	2
				
	 	  	(c)	 	Exchange Act Filings and April Offering Memorandum	  	2
				
	 	  	(d)	 	Corporate Power	  	3
				
	 	  	(e)	 	Authorization of the Securities Purchase Agreement, Registration Rights Agreement and Securities	  	3
				
	 	  	(f)	 	Authorization of the Conversion Shares and Warrant Shares	  	3
				
	 	  	(g)	 	Incorporation and Good Standing of the Company and its Subsidiaries	  	3
				
	 	  	(h)	 	Capitalization	  	4
				
	 	  	(i)	 	No Material Actions or Proceedings	  	4
				
	 	  	(j)	 	Non-Contravention of Existing Instruments; No Further Authorizations or Approvals Required	  	4
				
	 	  	(k)	 	No Other Rights to Require Registration of Securities	  	5
				
	 	  	(l)	 	Intellectual Property Rights	  	5
				
	 	  	(m)	 	No General Solicitation	  	5
				
	 	  	(n)	 	Insurance	  	6
				
	 	  	(o)	 	Recent Sales	  	6
				
	 	  	(p)	 	Related Party Transactions	  	6
				
	 	  	(q)	 	ERISA Compliance	  	6
				
	 	  	(r)	 	Tax Law Compliance	  	6
				
	 	  	(s)	 	All Necessary Permits, etc	  	7
				
	 	  	(t)	 	Outstanding Options, Warrants and Convertible Securities	  	7
				
	 	  	(u)	 	Violations of Contracts, Organizational Documents and Law	  	7
				
	 	  	(v)	 	No Unlawful Payments	  	7

  

 i 

 TABLE OF CONTENTS 
  
 (continued) 
  

							
	 	  	 	 	 	  	Page

	 	  	(w)	 	Market Stabilization	  	7
				
	 	  	(x)	 	Reporting and Listing	  	8
				
	 	  	(y)	 	Significant Subsidiaries	  	8
				
	 	  	(z)	 	Debt Securities Documents	  	8
				
	 	  	(aa)	 	Ranking	  	8
				
	 	  	(bb)	 	Designated Director	  	8
				
	 	  	(cc)	 	Search Committee	  	8
			
	Section 2.	  	Purchase, Sale and Delivery of the Securities	  	9
				
	 	  	(a)	 	The Securities	  	9
				
	 	  	(b)	 	The Closing	  	9
				
	 	  	(c)	 	Payment for the Securities; Delivery of the Securities	  	9
			
	Section 3.	  	Additional Covenants of the Company	  	9
				
	 	  	(a)	 	Use of Proceeds	  	9
				
	 	  	(b)	 	No Integration	  	9
				
	 	  	(c)	 	Reservation of Common Stock	  	10
				
	 	  	(d)	 	Transfer Agent	  	10
				
	 	  	(e)	 	Quotation of Conversion Shares and Warrant Shares	  	10
				
	 	  	(f)	 	Maintain Listing	  	10
				
	 	  	(g)	 	Appointment to Board of Directors	  	10
				
	 	  	(h)	 	Ranking; Additional Benefits	  	11
				
	 	  	(i)	 	Senior Management Change	  	11
				
	 	  	(j)	 	Compliance Certificate	  	12
				
	 	  	(k)	 	Notice of Defaults and Events of Default	  	12
				
	 	  	(l)	 	D&O Insurance	  	12
				
	 	  	(m)	 	Further Assurances	  	12
			
	Section 4.	  	Payment of Expenses	  	12

  

 ii 

 TABLE OF CONTENTS 
  
 (continued) 
  

							
	 	  	 	 	 	  	Page

	Section 5.	  	Conditions of the Obligations of the Purchasers	  	13
				
	 	  	(a)	 	Debentures	  	13
				
	 	  	(b)	 	Warrants	  	13
				
	 	  	(c)	 	Opinion of Counsel for the Company	  	13
				
	 	  	(d)	 	This Agreement and the Registration Rights Agreement	  	13
				
	 	  	(e)	 	Government Consents	  	13
				
	 	  	(f)	 	Board of Directors Consent	  	14
				
	 	  	(g)	 	Closing Fee	  	14
			
	Section 6.	  	Representations, Warranties and Covenants of the Purchasers	  	14
				
	 	  	(a)	 	Investment Purpose	  	14
				
	 	  	(b)	 	Accredited Investor Status	  	14
				
	 	  	(c)	 	No Current Registration	  	14
				
	 	  	(d)	 	No General Solicitation	  	14
				
	 	  	(e)	 	Legend	  	14
				
	 	  	(f)	 	Derivatives	  	15
				
	 	  	(g)	 	Partnership Power	  	15
				
	 	  	(h)	 	Subsequent Purchaser Notification	  	15
			
	Section 7.	  	Representations and Agreements to Survive Delivery	  	16
			
	Section 8.	  	Notices	  	16
			
	Section 9.	  	Transfer Restrictions; Successors	  	17
			
	Section 10.	  	Partial Unenforceability	  	17
			
	Section 11.	  	Governing Law Provisions; Consent to Jurisdiction	  	17
				
	 	  	(a)	 	Governing Law Provisions	  	17
				
	 	  	(b)	 	Consent to Jurisdiction	  	17
				
	 	  	(c)	 	Waiver of Jury Trial	  	18
			
	Section 12.	  	General Provisions	  	18

  

 iii 

 SECURITIES PURCHASE AGREEMENT 
  
 July 15, 2005 
  
 Friedman Fleischer & Lowe Capital Partners II, L.P. 
 FFL Executive Partners II, L.P. 
 FFL Parallel Fund II, L.P. 
 c/o Friedman Fleischer & Lowe, LLC 
 One Maritime Plaza 
 Suite 1000 
 San Francisco, CA 94111 
  
 Ladies and Gentlemen: 
  
 BearingPoint, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several
purchasers named in Schedule A attached hereto (the “Purchasers”) (a) $40,000,000 principal amount of its 0.50% Convertible Senior Subordinated Debentures due July 2010 in the form of Exhibit A attached hereto (the
“Debentures”), and (b) common stock purchase warrants in the form of Exhibit B attached hereto (the “Warrants” and, together with the Debentures, the “Securities”). 
  
 The Debentures are convertible into fully paid, non-assessable shares of
common stock, par value $0.01 per share, of the Company (the “Common Stock”) at the conversion price and on the other terms and conditions set forth therein. The Warrants are exercisable into shares of Common Stock at the exercise
price and on the other terms and conditions set forth therein. As used herein, the “Conversion Shares” means the shares of Common Stock into which the Debentures are convertible; and the “Warrant Shares” means the
shares of Common Stock into which the Warrants are exercisable. 
  
 The Securities will be offered and sold to the Purchasers without being registered under the Securities Act of 1933, as amended (the “Securities Act”), and the rules and regulations of the Securities and Exchange Commission
(the “Commission”) thereunder, in reliance upon an exemption therefrom. 
  
 Holders of the Securities (including the Purchasers and their successors and permitted assigns) will be entitled to the benefits of a Registration Rights Agreement, to be dated as of the Closing Date (as hereinafter
defined), between the Company and the Purchasers (the “Registration Rights Agreement”), pursuant to which the Company will agree to file with the Commission a shelf registration statement under the Securities Act (the
“Registration Statement”) covering the resale of the Conversion Shares and the Warrant Shares, and to use its reasonable best efforts to cause the Registration Statement to be declared effective. This Agreement, the Securities, the
Conversion Shares, the Warrant Shares and the Registration Rights Agreement are referred to herein, collectively, as the “Operative Documents”. 
  

As used in this Agreement, (a) the “April Offering Memorandum” means the Private Placement Memorandum, dated April 21, 2005
(including any amendments or supplements thereto), which describes the terms and conditions of the Company’s 5.00% 

 Convertible Senior Subordinated Debentures due April 15, 2025 (the “April Debt Securities”) issued
pursuant to an Indenture, dated as of April 27, 2005 (the “April Indenture”), by and between the Company and The Bank of New York, as Trustee; and (b) the “December Offering Memorandum” means the Offering
Memorandum, dated December 16, 2004 (including any amendments or supplements thereto), which describes the terms and conditions of (i) the Company’s 2.50% Series A Convertible Subordinated Debentures due December 15, 2024 (the
“Series A Debt Securities”) issued pursuant to an Indenture, dated as of December 22, 2004 (the “December Indenture” and, together with the April Indenture, the “Indentures”), by and between
the Company and The Bank of New York, as Trustee and (ii) the Company’s 2.75% Series B Convertible Subordinated Debentures due December 15, 2024 (the “Series B Debt Securities” and, together with the April Debt
Securities and the Series A Debt Securities, the “Debt Securities”) issued pursuant to the December Indenture. 
  
 The Company hereby confirms its agreements with the Purchasers as follows: 
  
 Section 1. Representations, Warranties and Covenants of the Company. 
  
 The Company hereby represents, warrants and covenants to each Purchaser as
follows: 
  
 (a) No Registration. Assuming the accuracy of
the representations and warranties of the Purchasers contained in Section 6 hereof, it is not necessary, in connection with the issuance and sale of the Securities to the Purchasers, the issuance of the Debenture Shares upon conversion of the
Debentures or the issuance of the Warrant Shares upon the exercise of the Warrants, in each case in the manner contemplated by this Agreement, the Debentures or the Warrants (as applicable), to register the Securities, the Conversion Shares or the
Warrant Shares under the Securities Act. 
  
 (b) No
Integration. Neither the Company nor any of its subsidiaries has, directly or through any agent, sold, offered for sale, solicited offers to buy or otherwise negotiated in respect of any “security” (as defined in the Securities Act)
that is or will be integrated with the sale of the Securities, the Conversion Shares or the Warrant Shares in a manner that would require registration under the Securities Act of the Securities, the Conversion Shares or the Warrant Shares.

  
 (c) Exchange Act Filings and April Offering Memorandum.
After taking into account the matters relating to the Company’s public filings with the Commission filed pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations
promulgated thereunder on Form 10-K, Form 10-Q and Form 8-K, including any amendments thereto (collectively, the “Exchange Act Filings”), that are addressed in the Form 12b-25 filed by the Company on March 17, 2005, the Form
8-K filed by the Company on March 17, 2005, the Form 8-K filed by the Company on April 20, 2005, and the Form 12b-25 filed by the Company on May 11, 2005, as of the Closing Date neither (i) the Exchange Act Filings, taken as a
whole, nor (ii) the April Offering Memorandum contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements made 
  

 2 

 therein, in light of the circumstances under which they were made, not misleading. Except as disclosed in writing to the
Purchasers prior to the Closing Date, the Company is not aware of any event occurring on or prior to the Closing Date (other than the transactions contemplated by the Operative Documents) that would require the filing of, or with respect to which
the Company intends to file, a Form 8-K or any other report, registration statement, schedule or proxy statement under the Exchange Act or the rules and regulations promulgated thereunder. 
  
 (d) Corporate Power. The Company has all requisite corporate power and
authority to enter into and deliver this Agreement, the Registration Rights Agreement and the Securities, to perform its obligations hereunder and thereunder, and to issue the Conversion Shares upon conversion of the Debentures and to issue the
Warrant Shares upon exercise of the Warrants in accordance with the terms thereof. 
  
 (e) Authorization of the Securities Purchase Agreement, Registration Rights Agreement and Securities. This Agreement, the Registration Rights Agreement and the Securities have been duly authorized, executed and
delivered by the Company, and constitute valid and binding agreements and obligations of the Company enforceable against the Company in accordance with their respective terms, except as enforcement thereof may be limited by bankruptcy, insolvency,
reorganization, moratorium, fraudulent transfer or other similar laws of general applicability relating to or affecting creditors’ rights or by general principles of equity. 
  
 (f) Authorization of the Conversion Shares and Warrant Shares. The shares of Common Stock issuable upon conversion of
the Debentures and the shares of Common Stock issuable upon exercise of the Warrants have been duly authorized and reserved and, when issued upon conversion of the Debentures in accordance with the terms of the Debentures or issued upon exercise of
the Warrants in accordance with the terms of the Warrants, will be validly issued, fully paid and non-assessable, and will conform in all respects to the description of the Common Stock contained in the Exchange Act Filings. The issuance of the
Conversion Shares and the Warrant Shares will not be subject to any preemptive rights, rights of first refusal or similar rights. 
  
 (g) Incorporation and Good Standing of the Company and its Subsidiaries. (1) The Company has been duly incorporated, is validly existing as a
corporation in good standing under the laws of the State of Delaware, has the corporate power and authority to own its property and to conduct its business as described in the April Offering Memorandum and is duly qualified to transact business and
is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing would not have a
Material Adverse Effect (as hereinafter defined), and (2) each Significant Subsidiary (as defined in Rule 1-02 of Regulation S-X) of the Company has been duly organized, is validly existing and in good standing under the laws of the
jurisdiction of its organization, has the power and authority to own its property and to conduct its business as described in the April Offering Memorandum and is duly qualified to transact business and is in good standing in each jurisdiction in
which the 
  

 3 

 conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that
the failure to be so qualified or be in good standing would not have a Material Adverse Effect; all of the equity interests of each Significant Subsidiary of the Company have been duly and validly authorized and issued, are fully paid and
non-assessable and, except as described in the April Offering Memorandum, are owned directly or through wholly owned subsidiaries by the Company, free and clear of all liens, encumbrances, equities or claims except such as may arise in connection
with any credit facility with the Company. 
  
 (h)
Capitalization. All of the issued and outstanding shares of capital stock of the Company have been duly authorized and validly issued, are fully paid and nonassessable. All of the issued and outstanding shares of capital stock of the
subsidiaries of the Company have been duly authorized and validly issued, are fully paid and nonassessable and are owned directly or indirectly by the Company, free and clear of all liens, encumbrances, equities or claims except such as may arise in
connection with any credit facility with the Company. 
  
 (i)
No Material Actions or Proceedings. Except as otherwise disclosed in the Exchange Act Filings or in writing to you if not required to be made in an Exchange Act Filing until after the Closing Date, there are no legal or governmental actions,
suits or proceedings pending or, to the Company’s knowledge, threatened (i) against or affecting the Company or any of its subsidiaries or (ii) which has as the subject thereof any officer or director (in their capacity as such) of,
or property owned or leased by, the Company or any of its subsidiaries, where in any such case (A) there is a reasonable possibility that such action, suit or proceeding might be determined adversely to the Company or such subsidiary and
(B) any such action, suit or proceeding, if so determined adversely, would reasonably be expected to result in a Material Adverse Effect or adversely affect the consummation of the transactions contemplated by this Agreement or the other
Operative Documents. No material labor dispute with the employees of the Company or any of its subsidiaries exists or, to the best of the Company’s knowledge, is threatened or imminent. 
  
 (j) Non-Contravention of Existing Instruments; No Further Authorizations
or Approvals Required. The Company’s execution, delivery and performance of the Operative Documents and consummation of the transactions contemplated thereby (including, without limitation, the issuance of the Conversion Shares upon
conversion of the Debentures and the issuance of the Warrant Shares upon exercise of the Warrants) (i) will not result in any violation of the provisions of the organizational documents of the Company or any subsidiary of the Company,
(ii) will not conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, or require the consent of any other party to, any indenture, mortgage, loan agreement, note, lease or other
agreement or instrument to which the Company or any of its subsidiaries is a party or by which it or any of them may be bound or to which any of the property or assets of the Company or any of its subsidiaries is subject, including, without
limitation, the Debt Securities or the Indentures, and (iii) will not result in any violation of any law, statute or order, rule or regulation of any court or governmental agency or body applicable to the Company or any subsidiary of the
Company, except in the case of clause 
  

 4 

 (ii) only, for such conflicts, breaches, violations or defaults as would not reasonably be expected to have, either
individually or in the aggregate, a material adverse change, or any development involving a prospective material adverse change, in or affecting the management, condition (financial or otherwise), stockholders’ equity, results of operations,
business or prospects of the Company and its subsidiaries, taken as a whole (a “Material Adverse Effect”). No consent, approval, authorization or other order of, or registration or filing with, any court or other governmental or
regulatory authority or agency is required for the Company’s execution, delivery and performance of the Operative Documents and consummation of the transactions contemplated thereby, except (1) with respect to the transactions contemplated
by the Registration Rights Agreement, as may be required under the Securities Act and the rules and regulations promulgated thereunder and (2) such consents, approvals, authorizations, orders, filings or registrations as may be required under
state securities or Blue Sky laws in connection with the offering of the Securities by the Company. 
  
 (k) No Other Rights to Require Registration of Securities. There are no contracts, agreements or understandings between the Company and any person
granting such person the right (i) to require the Company to file a registration statement under the Securities Act with respect to any securities of the Company or (ii) to require the Company to include such securities with the Conversion
Shares and the Warrant Shares to be registered for resale by means of the Registration Statement, except in the case of clause (i) above (A) the Resale Registration Rights Agreement, dated December 22, 2004, between the Company, Banc
of America Securities LLC and J.P. Morgan Securities Inc., (B) the Registration Rights Agreement, dated April 27, 2005, between the Company, Morgan Stanley & Co. Incorporated, UBS Securities LLC and Needham & Company,
LLC, and (C) the registration rights granted to Mr. Harry You, Ms. Judy Ethell and Ms. Connie Weaver pursuant to the restricted stock unit and stock option awards granted to them. 
  
 (l) Intellectual Property Rights. Except as would not result in a
Material Adverse Effect, the Company and its subsidiaries own or possess sufficient trademarks, trade names, patent rights, copyrights, domain names, licenses, approvals, trade secrets and other similar rights (collectively, “Intellectual
Property Rights”) reasonably necessary to conduct their businesses as now conducted; and the expected expiration of any of such Intellectual Property Rights would not result in a Material Adverse Effect. Neither the Company nor any of its
subsidiaries has received any notice of infringement or conflict with asserted Intellectual Property Rights of others, which infringement or conflict, if the subject of an unfavorable decision, would result in a Material Adverse Effect. Except as
would not result in a Material Adverse Effect, none of the technology employed by the Company has been obtained or is being used by the Company in violation of any contractual obligation binding on the Company or, to the Company’s knowledge,
any of its officers, directors or employees or otherwise in violation of the rights of any persons. 
  
 (m) No General Solicitation. Neither the Company nor any of its affiliates (as defined in Rule 501(b) of Regulation D under the Securities Act
(“Regulation D”)), has, 
  

 5 

 directly or through an agent, engaged in any form of general solicitation or general advertising (as those terms are used
in Regulation D) in connection with the offering of the Securities, the Conversion Shares or the Warrant Shares, or in any manner involving a public offering within the meaning of Section 4(2) of the Securities Act; the Company has not entered
into any contractual arrangement with respect to the distribution of the Securities, the Conversion Shares or the Warrant Shares except for this Agreement, and the Company will not enter into any such arrangement except for the Registration Rights
Agreement. 
  
 (n) Insurance. Each of the Company and its
subsidiaries are insured by institutions believed by the Company to be recognized, financially sound and reputable institutions with policies in such amounts and with such deductibles and covering such risks as each of the Company and its
subsidiaries believes is adequate and customary for their businesses. 
  
 (o) Recent Sales. Except for the Debt Securities and as disclosed in the Exchange Act Filings, the Company has not sold or issued any shares of Common Stock, any security convertible into shares of Common Stock or any security of the
same class as the Securities during the six-month period preceding the Closing Date, including any sales pursuant to Rule 144A or under Regulations D or S of the Securities Act, other than shares or options issued pursuant to the Company’s
employee stock purchase, stock option, stock bonus or other stock plans or arrangements or stock awards to the persons identified in Section 1(k). 
  
 (p) Related Party Transactions. There are no business relationships or related-party transactions involving the Company or any subsidiary of the
Company or any other person required to be described in the documents incorporated by reference in the April Offering Memorandum pursuant to Item 404 of Regulation S-K which have not been described as required. 
  
 (q) ERISA Compliance. Except as would not reasonably be expected to
result in a Material Adverse Effect, neither the Company, its subsidiaries nor any of their ERISA Affiliates has incurred or reasonably expects to incur any liability under Title IV of the Employee Retirement Income Security Act of 1974, as amended
(“ERISA”), with respect to termination of, or withdrawal from, any “defined benefit plan” (as defined in Section 3(35) of ERISA). “ERISA Affiliate” means, with respect to the Company or a subsidiary
of the Company, any member of any group of organizations described in Sections 414(b), (c), (m) or (o) of the Internal Revenue Code of 1986, as amended, and the regulations and published interpretations thereunder (the
“Code”), of which the Company or such subsidiary is a member. 
  
 (r) Tax Law Compliance. Except with respect to the employee tax equalization issues referred to in the Form 8-K filed by the Company on April 20, 2005, the Company has filed all federal, state and local
income and franchise tax returns required to be filed through the Closing Date and has paid all taxes shown as due thereon other than those taxes contested in good faith, and no tax deficiency has been determined adversely to the Company or any of
its subsidiaries that has had (nor does the Company 
  

 6 

 have any knowledge of any tax deficiency that, if determined adversely to the Company or any of its subsidiaries, might
have) or could reasonably be expected to have a Material Adverse Effect. 
  
 (s) All Necessary Permits, etc. The Company and its subsidiaries possess such valid and current certificates, authorizations or permits issued by the appropriate state, federal or foreign regulatory agencies or
bodies necessary to conduct their respective businesses, except as would not, individually or in the aggregate, result in a Material Adverse Effect, and neither the Company nor any subsidiary has received any notice of proceedings relating to the
revocation or modification of, or non-compliance with, any such certificate, authorization or permit which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would result in a Material Adverse Effect.

  
 (t) Outstanding Options, Warrants and Convertible
Securities. Except for the Securities and as disclosed in the Exchange Act Filings and pursuant to the Company’s employee stock option purchase, stock option, stock bonus and other employee stock plans or arrangements and as disclosed in
Section 1(k), there are not currently, and will not be as a result of the offering of the Securities, any outstanding subscriptions, rights, warrants, calls, commitments of sales or options to acquire, or instruments convertible into or
exchangeable for, any capital stock or equity interest of the Company or any of its subsidiaries. 
  
 (u) Violations of Contracts, Organizational Documents and Law. Except as disclosed in Exchange Act Filings, neither the Company nor any of its
subsidiaries (i) is in violation of its charter, by-laws or applicable organizational documents, (ii) is in default in any material respect, and no event has occurred that, with notice or lapse of time or both, would constitute such a
default, in the due performance or observance of any term, covenant, condition or other obligation contained in any material indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which it is a party or by which it is
bound or to which any of its properties or assets is subject, or (iii) is in violation in any material respect of any law, ordinance, governmental rule, regulation or court decree to which it or its property or assets may be subject or has
failed to obtain or maintain any material license, permit, certificate, franchise or other governmental authorization or permit necessary to the ownership of its property or to the conduct of its business. 
  
 (v) No Unlawful Payments. Neither the Company nor, to the knowledge of
the Company, any director, officer, agent, employee or other person associated with or acting on behalf of the Company has (i) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to
political activity; (ii) made any direct or indirect unlawful payment to any foreign or domestic government official or employee from corporate funds; or (iii) made any bribe, rebate, payoff, influence payment, kickback or other unlawful
payment. 
  
 (w) Market Stabilization. Prior to the Closing
Date, neither the Company nor any of its affiliates nor any person acting on its or their behalf has taken any action that is 
  

 7 

 designed to or that has constituted or that might have been expected to cause or result in stabilization or manipulation
of the price of any security of the Company in connection with the offering of the Securities. 
  
 (x) Reporting and Listing. The Company is subject to Section 13 or 15(d) of the Exchange Act and files reports with the Commission on the EDGAR System. The Common Stock is registered pursuant to
Section 12(g) of the Exchange Act and the outstanding shares of Common Stock are listed on the New York Stock Exchange (the “NYSE”). 
  
 (y) Significant Subsidiaries. The Company has no significant subsidiaries as determined by reference to Rule 1-02(w) of Regulation S-X. 

 
 (z) Debt Securities Documents. The Company has provided to the
Purchasers true, complete and correct copies of (i) each of the Indentures, (ii) a form of each class of the Debt Securities issued pursuant to each of the Indentures, (iii) the April Offering Memorandum and the December Offering
Memorandum, (iv) all documents, instruments and other agreements executed and/or delivered in connection with each of the Indentures and the Debt Securities (including any registration rights agreement or investor rights agreement), and
(v) all amendments, waivers and side letters relating to any of the foregoing or affecting the terms thereof (all of the foregoing being referred to herein, collectively, as the “Debt Securities Documents”). 
  
 (aa) Ranking. The Debentures and all obligations of the Company
thereunder (i) constitute “Senior Debt” as defined in and for purposes of the December Indenture and (ii) constitute “Senior Subordinated Debt” as defined in and for purposes of the April Indenture. The Debentures rank
(A) pari passu in right of payment to the April Debt Securities and (B) senior in right of payment to the Series A Debt Securities and the Series B Debt Securities. There is no term, provision or other agreement included in the Indentures
or any of the other Debt Securities Documents that prohibits or otherwise restricts the right or the ability of the Company (1) to make payments on or in respect of the Debentures or (2) to issue and deliver the Conversion Shares upon
conversion of the Debentures or to issue and deliver the Warrant Shares upon exercise of the Warrants. 
  
 (bb) Designated Director. The Board of Directors of the Company (the “Board”) has duly authorized the increase in the size of the
Board and the election of the Designated Director (as defined below) promptly following the Closing as contemplated by Section 3(g) below. 
  
 (cc) Search Committee. The Board has specifically reviewed and considered the terms and provisions of Section 3(i) below, and the Board has
determined that if a Search Committee of the type referred to in Section 3(i) below was formed on the Closing Date, it would include the Designated Director on the Search Committee. 
  
 The Company acknowledges that the Purchasers and, for purposes of the opinion to be delivered pursuant to Section 5
hereof, counsel to the Company (but only with respect to representations of fact), will rely upon the accuracy and truthfulness of the foregoing representations and hereby consents to such reliance. 
  

 8 

 Section 2. Purchase, Sale and Delivery of the Securities. 
  
 (a) The Securities. The Company agrees to issue and sell to the
several Purchasers the Securities upon the terms herein set forth. On the basis of the representations, warranties and agreements herein contained, and upon the terms but subject to the conditions herein set forth, the Purchasers agree, severally
and not jointly, to purchase from the Company (i) the respective principal amount of the Debentures set forth opposite their names under the heading “Aggregate Principal Amount of Debentures to be Purchased” on Schedule A and
(ii) the Warrants exercisable into the number of shares of Common Stock set forth opposite their names under the heading “Shares of Common Stock Issuable Upon Exercise of Warrants” on Schedule A. The purchase price (the
“Purchase Price”) to be paid by each Purchaser for the Securities to be purchased by such Purchaser shall be equal to the principal amount of the Debentures which such Purchaser is purchasing hereunder. 
  
 (b) The Closing. The closing (the “Closing”) of the
purchase and sale of the Securities shall be made at the offices of Bingham McCutchen LLP, 399 Park Avenue, New York, New York 10022 (or such other place as may be agreed to by the Company and the Purchasers) at 10:00 a.m. New York time, on
July 15, 2005, or such other time and date as the Purchasers and the Company may agree (the time and date of the Closing are called the “Closing Date”). 
  
 (c) Payment for the Securities; Delivery of the Securities. On the Closing Date, (i) each Purchaser shall pay
the Purchase Price for the Securities to be issued and sold to it at the Closing by wire transfer of immediately available funds to the Company, in accordance with the Company’s written wiring instructions, against delivery of duly executed
Securities which such Purchaser is purchasing and (ii) the Company shall deliver such certificates duly executed on behalf of the Company to each Purchaser against delivery of such Purchase Price. 
  
 Section 3. Additional Covenants of the Company. 
  
 The Company further covenants and agrees with each Purchaser as follows:

  
 (a) Use of Proceeds. The Company shall use the
proceeds it receives from the issuance and sale of the Securities hereunder to fund future growth and for working capital and general corporate purposes. 
  
 (b) No Integration. The Company will not, and will cause its subsidiaries not to, sell, offer for sale or solicit offers to buy or otherwise
negotiate in respect of any “security” (as defined in the Securities Act) in a transaction that could reasonably be expected to be integrated with the sale of the Securities in a manner that would require the registration under the
Securities Act of the Securities. 
  

 9 

 (c) Reservation of Common Stock. The Company shall at all times from and after the Closing Date
maintain a reserve from its duly authorized shares of Common Stock for issuance of the Conversion Shares upon the full conversion of the Debentures and issuance of the Warrant Shares upon full exercise of the Warrants in such amount as may be
required to fulfill its obligations under the Debentures and the Warrants. In the event that at any time the then authorized shares of Common Stock are insufficient for the Company to satisfy its obligations to issue the Conversion Shares upon full
conversion of the Debentures and to issue the Warrant Shares upon full exercise of the Warrants, the Company shall promptly take such actions as may be required to increase the number of authorized shares of Common Stock so that it may satisfy such
obligations. 
  
 (d) Transfer Agent. Promptly following the
Closing Date, the Company shall issue irrevocable transfer instructions to its transfer agent to issue certificates, registered in the name of each of the Purchasers or its nominee, for the Conversion Shares and the Warrant Shares in such amounts as
specified from time to time by each Purchaser to the Company upon conversion of the Debentures or upon exercise of the Warrants (as applicable) in accordance with the terms thereof. 
  
 (e) Quotation of Conversion Shares and Warrant Shares. The Company will use its commercially reasonable efforts to
have the Conversion Shares and the Warrant Shares approved by the NYSE for quotation as soon as practicable following the Closing Date. 
  
 (f) Maintain Listing. The Company will use commercially reasonable efforts to (i) maintain the listing and trading of the Common Stock on the
NYSE or other securities exchange or automated quotation system for so long as the Company qualifies for such listing under the rules and regulations of the NYSE or such other securities exchange or automated quotation system and (ii) comply in
all material respects with the Company’s reporting, filing and other obligations under the rules and regulations of the NYSE or such other securities exchange or automated quotation system. 
  
 (g) Appointment to Board of Directors. As promptly as is reasonably
possible following the Closing Date, the Company shall increase the size of its board of directors (the “Board”) by one and fill the vacancy with Mr. Spencer C. Fleischer (the “Designated Director”). The
Designated Director shall be in a class whose term ends in 2007. If Mr. Fleischer (or any successor Designated Director) shall at any time cease to be affiliated with Friedman Fleischer & Lowe Capital Partners II, L.P. (the
“Specified Fund”), or shall cease to be able to serve on the Board by reason of his resignation, death, incapacity, disability, disqualification or removal, or as a result of a conflict of interest (but not as a result of the
Designated Director’s failure to be re-elected by the stockholders of the Company), the Specified Fund shall be entitled to nominate a new individual (subject to the approval of the Board not to be unreasonably withheld) to serve as a member of
the Board and the Company shall fill the vacancy created by such departed Designated Director with such nominated individual. Any such nominated individual that is elected to serve on the Board shall be deemed to be the Designated Director
hereunder. For so long as the Specified Fund and/or its affiliates together hold 
  

 10 

 at least 40% of the original principal amount of the Debentures issued on the Closing Date, the Specified Fund shall have
the right to designate a Designated Director as provided in the third sentence of this Section 3(g), and the Board shall, consistent with the reasonable exercise of its fiduciary duties, recommend at each meeting of stockholders at which a
Designated Director is to be elected to include a Designated Director in the Board’s slate of nominees for election to the Board or to fill a vacancy left by a departed Designated Director, in each case in order so that there may be a
Designated Director, and shall not take any action which is inconsistent with making such recommendation. In the event that the stockholders do not elect a Designated Director at a meeting of stockholders at which such Designated Director is
nominated for election, then the Specified Fund shall have the right to designate a new Designated Director as provided in the third sentence of this Section 3(g). If the Specified Fund and/or its affiliates together hold less than 40% of the
original principal amount of the Debentures issued on the Closing Date, the Designated Director shall promptly upon request of the Company submit his or her resignation to the Board. 
  
 (h) Ranking; Additional Benefits. The Debentures and the obligations of the Company thereunder shall at all times
rank (i) pari passu with the “Senior Subordinated Debt” (as defined in the April Indenture) in right of payment, covenants, priority of liens and other collateral, if any, and distributions upon liquidation or dissolution of the
Company, and (ii) senior to the “Subordinated Debt” (as defined in the April Indenture) in right of payment, covenants, priority of liens and other collateral, if any, and distributions upon liquidation or dissolution of the Company,
and the Company shall take all action required, or that the holders of the Debentures deem reasonably necessary or desirable, to maintain the pari passu and senior status (as hereinabove described) of the Debentures and the obligations of the
Company thereunder. The Company shall not offer, extend or provide any rights, benefits, payments or fees (other than those expressly set forth in the Debt Securities and the Indentures on the Closing Date) to a holder of Senior Subordinated Debt or
Subordinated Debt, or exchange, substitute or replace any Senior Subordinated Debt or Subordinated Debt for new or existing securities of the Company (except upon exchange or conversion thereof as expressly provided for in the Debt Securities and
the Indentures as of the Closing Date), unless such offer, extension, provision, exchange, substitution or replacement is provided to the holders of the Debentures, taking into account the relative priorities set forth herein. In any such event, the
Company and the holders of the Debentures shall negotiate in good faith any necessary or appropriate amendments or modifications to the Debentures, or the terms of the exchange, substitute or replacement securities, taking into account the totality
of the circumstances and other equitable considerations, to implement the provisions of the immediately preceding sentence. 
  
 (i) Senior Management Change. The Company acknowledges that, if for any reason Mr. Harry You ceases to be the Chief Executive Officer of the
Company, the Purchasers desire to have the Designated Director serve on the Search Committee (if any) formed by the Board to identify and nominate a replacement Chief Executive Officer. The Company hereby agrees that, if at the time of formation of
any such Search Committee a Designated Director is in office, the Company will recommend to the Board 
  

 11 

 that the Board should give due consideration to appointing the Designated Director to the Search Committee, and that,
absent reasonable justification to the contrary, the Board should appoint the Designated Director to the Search Committee. 
  
 (j) Compliance Certificate. The Company shall deliver to the holders of the Debentures within 120 days after the end of each fiscal year of the
Company (beginning with the fiscal year ending December 31, 2005) a certificate signed by an executive officer (as defined in Section 501(f) of the Securities Act) of the Company stating whether or not, to the knowledge of such executive
officer, the Company is in default in the performance or observance of any of the terms, provisions or conditions of this Agreement or the Debentures (without regard to any period of grace or requirement of notice provided thereunder) and, if the
Company shall be in default, specifying all such defaults and the nature and status thereof. 
  
 (k) Notice of Defaults and Events of Default. The Company shall, so long as any of the Debentures are outstanding, deliver to the Purchasers, forthwith upon any executive officer of the Company becoming aware
of any default or Event of Default (as defined in the Debentures) in respect of the performance or observance of any covenant, agreement or condition contained in this Agreement or the Debentures, but in any event not later than twenty
(20) business days after the occurrence thereof, a certificate signed by an executive officer of the Company specifying such default or Event of Default and what action the Company is taking or proposes to take with respect thereto. 

 
 (l) D&O Insurance. At all times during which the holders of the
Debentures are entitled to appoint a Designated Director, the Company shall maintain director and officer liability insurance coverage providing coverage at such levels and in such amounts that are the same as (or better than) the levels and amounts
provided by the insurance coverage in effect on the Closing Date; provided, however, that the Company shall not be required to pay aggregate premiums for such director and officer liability insurance in excess of 200% of the premiums
for such insurance as of the Closing Date. 
  
 (m) Further
Assurances. The Company will execute and deliver such further instruments and do such further acts as may be reasonably necessary or proper to carry out more effectively the purposes of this Agreement. 
  
 Section 4. Payment of Expenses. 
  
 The Company agrees to pay all costs, fees and expenses of the Company and the
Purchasers incurred in connection with the performance of their respective obligations hereunder and in connection with the transactions contemplated hereby (provided, that in the case of the Purchasers, this obligation of the Company shall
only apply to those costs, fees and expenses of the Purchasers incurred prior to and/or on the Closing Date), including without limitation, (i) all expenses incident to the issuance and delivery of the Securities, the issuance and delivery of
the Conversion Shares upon conversion of the Debentures and the issuance and delivery of the Warrant Shares upon exercise of the Warrants, (ii) all necessary issue, transfer and other stamp taxes in connection with the issuance and delivery of
the Securities, the Conversion Shares and the Warrant Shares, 
  

 12 

 (iii) all fees, costs and expenses of the Company’s counsel, independent public or certified public accountants
and other advisors, (iv) all fees, costs and expenses of the Purchasers (including the reasonable fees and expenses of the Purchasers’ accountants, financial advisors and attorneys) incurred in connection with the negotiation, preparation,
execution and delivery of each of the Operative Documents, (v) all filing fees, attorneys’ fees and expenses incurred by the Company or the Purchasers in connection with qualifying or registering (or obtaining exemptions from the
qualification or registration of) all or any part of the Securities for offer and sale under the state securities or blue sky laws and (vi) the fees and expenses associated with listing the Conversion Shares and the Warrant Shares on the NYSE;
provided, however, that the obligation of the Company under this Section 4 to reimburse the Purchasers for their fees, costs and expenses shall not exceed $1,000,000 in the aggregate; and provided, further, that no
Purchaser shall receive any such reimbursement unless it has satisfied its obligations under Section 2(c). 
  
 Section 5. Conditions of the Obligations of the Purchasers. 
  
 The obligations of the several Purchasers to purchase and pay for the Securities as provided herein on the Closing Date shall be subject to the accuracy
in all material respects of the representations and warranties on the part of the Company set forth in Section 1 hereof as of the date such representations and warranties are made and as though made on and as of the Closing Date, to the timely
performance by the Company of its covenants and other material obligations hereunder to be performed on or prior to the Closing Date, and to each of the following additional conditions: 
  
 (a) Debentures. Each of the Purchasers shall have received a duly executed Debenture issued in the name of such
Purchaser in the aggregate principal amount set forth under the heading “Aggregate Principal Amount of Debentures to be Purchased” on Schedule A opposite the name of such Purchaser. 
  
 (b) Warrants. Each of the Purchasers shall have received a duly
executed Warrant issued in the name of such Purchaser to acquire the number of shares of Common Stock set forth under the heading “Shares of Common Stock Issuable Upon Exercise of Warrants” on Schedule A opposite the name of such
Purchaser. 
  
 (c) Opinion of Counsel for the Company. The
Purchasers shall have received the favorable opinion of internal company counsel, dated as of such Closing Date and addressed to the Purchasers, the form of which is attached as Exhibit A. 
  
 (d) This Agreement and the Registration Rights Agreement. The Company
shall have executed and delivered to the Purchasers a counterpart of this Agreement and the Registration Rights Agreement. 
  
 (e) Government Consents. The Company shall have made all filings or notices with, and received all consents or approvals from, each governmental or
regulatory agency or authority that it is required to make or receive in connection with the execution, delivery or performance by the Company of the transactions contemplated by the Operative Agreements. 
  

 13 

 (f) Board of Directors Consent. The Board of Directors of the Company shall have adopted
resolutions to approve the transactions contemplated by this Agreement and the other Operative Documents (including resolutions that authorize and reserve 100% of the aggregate number of shares of Common Stock issuable upon full conversion of all of
the Debentures and full exercise of all of the Warrants), and the other matters referred to herein, and such resolutions shall be in form and substance satisfactory to the Purchasers. 
  
 (g) Closing Fee. The Company shall have paid to the Purchasers a non-refundable closing fee so that the total amount
of expense reimbursement under Section 4 and non-refundable closing fee shall equal $1,000,000. 
  
 Section 6. Representations, Warranties and Covenants of the Purchasers. 
  
 Each of the Purchasers represents, warrants and covenants as follows: 
  
 (a) Investment Purpose. The Securities that are being acquired by such Purchaser hereunder are being acquired by it,
and the Conversion Shares issuable upon conversion of the Debentures and the Warrant Shares issuable upon exercise of the Warrants will be acquired by such Purchaser, for its own account for investment and not with a view to the distribution
thereof. Such Purchaser understands that neither the Securities, the Conversion Shares nor the Warrant Shares have been registered under the Securities Act on the ground that the offer and sale of the Securities to it, and the issuance of the
Conversion Shares to it upon conversion of the Debentures and the issuance of the Warrant Shares to it upon exercise of the Warrants, are exempt from the registration requirements of the Securities Act under Section 4(2) thereof as a
transaction not involving any public offering. Such Purchaser understands that the Company’s reliance on such exemption is predicated in part on its representations which are contained herein. 
  
 (b) Accredited Investor Status. Such Purchaser is an “accredited
investor” (as defined in Rule 501 of Regulation D). 
  
 (c)
No Current Registration. Such Purchaser understands that the Securities, the Conversion Shares and the Warrant Shares have not been and will not be registered under the Securities Act in connection with the initial offering of the Securities.

  
 (d) No General Solicitation. Such Purchaser has not and
will not offer or sell the Securities in the United States by means of any form of general solicitation or general advertising within the meaning of Rule 502(c) of Regulation D, including (i) any advertisement, article, notice or other
communication published in any newspaper, magazine or similar medium or broadcast over television or radio, or (ii) any seminar or meeting whose attendees have been invited by any general solicitation or general advertising in the United
States. 
  
 (e) Legend. Such Purchaser understands that the
Securities and, until such time as the Conversion Shares and the Warrant Shares have been registered under the Securities Act as contemplated by the Registration Rights Agreement or otherwise may 
  

 14 

 be sold pursuant to Rule 144 under the Securities Act without any restriction as to the number of securities as of a
particular date that can then be immediately sold, the Conversion Shares and the Warrant Shares shall bear a legend substantially similar to the following (in addition to any legend required under applicable state securities laws): 
  
 THE SECURITIES EVIDENCED HEREBY HAVE NOT BEEN REGISTERED UNDER THE UNITED
STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED, UNLESS AND UNTIL REGISTERED UNDER THE SECURITIES ACT OR THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL
REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. 
  
 The Company shall be obligated to reissue promptly unlegended certificates at the request of any holder thereof if such holder shall have obtained an opinion of counsel reasonably satisfactory to the Company to the effect that the
securities proposed to be disposed of may lawfully be so disposed of without registration, qualification or legend. 
  
 (f) Derivatives. For a period of one (1) year following the Closing Date, the Purchasers will not enter into any Short Sales (as defined
below) with respect to the Conversion Shares or the Warrant Shares; provided, however, that the foregoing will not prohibit the Purchasers from entering into a forward sale or similar transaction at any time when the Debentures are
convertible or the Warrants are exercisable, and will not prohibit any purchaser in any such transaction from using any hedging or similar transactions to protect its position in respect of the Debentures, the Warrants, the Conversion Shares or the
Warrant Shares. As used herein, the term “Short Sales” include, without limitation, all “short sales” as defined in Rule 3b-3 of the Exchange Act and all types of direct and indirect stock pledges, forward sale contracts,
options, puts, calls, short sales, swaps and similar arrangements (including on a total return basis), and sales and other transactions through non-US broker dealers or foreign regulated brokers. 
  
 (g) Partnership Power. Each of the Purchasers has all requisite
limited partnership power and authority to enter into and deliver this Agreement and the Registration Rights Agreement, and to perform its obligations hereunder and thereunder. 
  
 (h) Subsequent Purchaser Notification. The Purchasers shall take reasonable steps and cause each of its affiliates
(as such term is defined in Rule 501(b) of Regulation D) to take reasonable steps to inform persons acquiring the Securities, the Conversion Shares or the Warrant Shares from the Purchaser or any of such affiliates that the Securities, the
Conversion Shares or the Warrant Shares (as applicable) (i) have not been registered under the Securities Act, (ii) are being sold to them without registration under the Securities Act in reliance on Rule 144 or in accordance with another
exemption from registration under the Securities Act, as the case may be, and (iii) may not be offered, sold or otherwise transferred except (A) to the Company or any of its subsidiaries, (B)
  

 15 

 pursuant to a registration statement declared effective by the Commission under the Securities Act or (C) pursuant
to an available exemption from registration under the Securities Act. 
  
 Section 7. Representations and Agreements to Survive Delivery. 
  
 The agreements, representations, warranties and other statements of the Company and the several Purchasers set forth herein shall survive the Closing and the issuance, delivery and conversion of the Securities.

  
 Section 8. Notices. 
  
 All communications hereunder shall be in writing and shall be mailed, hand
delivered or telecopied and confirmed to the parties hereto as follows: 
  
 If to the Purchasers: 
  
 c/o
Friedman Fleischer & Lowe LLC 
 One Maritime Plaza 
 Suite 1000 
 San Francisco, CA 94111 
 Facsimile: (415) 402-2111 
 Attention:
Spencer C. Fleischer 
  
 with a copy to: 
  
 Bingham McCutchen LLP 
 399 Park Avenue 
 New York, NY 10022

 Facsimile: (212) 752-5378 
 Attention: Neil W. Townsend, Esq. 
  
 If to the Company:

  
 BearingPoint, Inc. 
 1676 International Drive 
 McLean, VA 22102

 Facsimile: (703) 747-3917 
 Attention: David W. Black, Esq. 
  
 with a copy to:

  
 BearingPoint, Inc. 
 1676 International Drive 
 McLean, VA 22102

 Facsimile: (703) 747-3917 
 Attention: Chief Financial Officer 
  

 16 

 Any party hereto may change the address for receipt of communications by giving written notice to the
others. 
  
 Section 9. Transfer Restrictions; Successors.

  
 No Purchaser shall make any transfer or other disposition
of all or any portion of the Securities, the Conversion Shares or the Warrant Shares unless and until: (a) there is then in effect a registration statement under the Securities Act covering such proposed disposition and such disposition is made
in accordance with such registration statement; or (b)(i) the transferee has agreed in writing to be bound by the terms of this Agreement, (ii) such Purchaser shall have notified the Company of the proposed disposition and shall have furnished
the Company with a reasonably detailed statement of the circumstances surrounding the proposed disposition, and (iii) if requested by the Company, such Purchaser shall have furnished the Company with an opinion of counsel, reasonably
satisfactory to the Company, that such disposition will not require registration of such securities under the Securities Act. 
  
 This Agreement and the provisions hereof shall inure to the benefit of, and be binding upon, the parties hereto and their respective successors and
permitted assigns. The Company may not assign this Agreement or any of its rights or obligations hereunder without the prior written consent of the Purchasers. Any Purchaser may assign its rights under this Agreement to any person or entity to which
such Purchaser transfers any Securities, Conversion Shares or Warrant Shares in accordance with the terms of this Section 9. 
  
 Section 10. Partial Unenforceability. 
  
 The invalidity or unenforceability of any Section, paragraph or provision of this Agreement shall not affect the validity or enforceability of any other
Section, paragraph or provision hereof. If any Section, paragraph or provision of this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are
necessary to make it valid and enforceable. 
  
 Section 11.
Governing Law Provisions; Consent to Jurisdiction. 
  
 (a)
Governing Law Provisions. This Agreement shall be governed by, and construed in accordance with, the law of the State of New York, without giving effect to any conflict of law provisions thereof other than New York General Obligations Laws
Sections 5-1401 and 5-1402. 
  
 (b) Consent to
Jurisdiction. Any legal suit, action or proceeding arising out of or based upon this Agreement, any of the other Operative Documents or any of the transactions contemplated hereby or thereby (“Related Proceedings”) may be
instituted in the federal courts of the United States of America located in the City and County of New York or the State of Delaware (collectively, the “Specified Courts”), and each party irrevocably submits to the exclusive
jurisdiction (except for proceedings instituted 
  

 17 

 in regard to the enforcement of a judgment of any such court, as to which such jurisdiction is non-exclusive) of such
courts in any such suit, action or proceeding. Service of any process, summons, notice or document by mail to such party’s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any
such court. The parties irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such
court that any such suit, action or other proceeding brought in any such court has been brought in an inconvenient forum. 
  
 (c) Waiver of Jury Trial. The parties hereby irrevocably waive all right to a trial by jury in any action, proceeding or counterclaim arising out
of or relating to this Agreement or any of the other Operative Documents or the transactions contemplated hereby or thereby. 
  
 Section 12. General Provisions. 
  
 This Agreement and the other Operative Documents constitute the entire agreement of the parties to this Agreement and supersedes all prior written or oral
and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof and thereof. This Agreement may be executed in two or more counterparts, each one of which shall be an original, with the same effect
as if the signatures thereto and hereto were upon the same instrument. This Agreement may not be amended or modified unless in writing by the Company and the holders of at least two-thirds of the aggregate outstanding principal amount of the
Debentures. The Section headings herein are for the convenience of the parties only and shall not affect the construction or interpretation of this Agreement. 
  

The parties acknowledge and agree (i) that the terms of the Confidentiality Agreement, dated April 15, 2005 (the “Confidentiality
Agreement”), between the Company and Friedman Fleischer & Lowe LLC (“FFL”), shall remain in full force and effect with respect to the Evaluation Material (as defined therein) furnished by the Company or its
Representatives (as defined therein) to FFL, the Purchasers or their Representatives on or prior to the Closing Date, (ii) that the terms of the Confidentiality Agreement shall not apply to any Evaluation Material furnished by the Company or
its Representatives to FFL, the Purchasers or their Representatives after the Closing Date and (iii) that nothing contained in the Confidentiality Agreement (including, without limitation, Section 6(a)(i) thereof) or otherwise shall at any
time prohibit FFL or the Purchasers from trading in securities of the Company so long as (a) FFL and the Purchasers are not prohibited from trading in such securities under applicable securities laws and (b) trading in such securities is
not prohibited by Section 6(a)(ii) or Section 6(d) of the Confidentiality Agreement. 
  
 Each of the parties hereto acknowledges that it is a sophisticated business person that was adequately represented by counsel during negotiations regarding the provisions hereof and is fully informed regarding said
provisions. 
  

 18 

 If the foregoing is in accordance with your understanding of our agreement, kindly sign and return to the
Company the enclosed copies hereof, whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms. 
  

			
	Very truly yours,
	
	BEARINGPOINT, INC.
		
	By:	 	 /s/ Harry L. You

	Name:	 	Harry L. You
	Title:	 	Chief Executive Officer

  

 19 

 The foregoing Securities Purchase Agreement is hereby confirmed and accepted by the Purchasers as of the
date first above written. 
  

			
	 FRIEDMAN FLEISCHER & LOWE
 CAPITAL PARTNERS II, L.P.

	 By: Friedman Fleischer & Lowe GP II,
 L.P., its general partner

	 By: Friedman Fleischer & Lowe GP II,
 LLC, its general partner

		
	By:	 	 /s/ Spencer Fleischer

	Name:	 	Spencer Fleischer
	Title:	 	Vice Chairman
	
	FFL PARALLEL FUND II, L.P.
	 By: Friedman Fleischer & Lowe GP II, LP,
 its general partner

	 By: Friedman Fleischer & Lowe GP II,
 LLC, its general partner

		
	By:	 	 /s/ Spencer Fleischer

	Name:	 	Spencer Fleischer
	Title:	 	Vice Chairman
	
	FFL EXECUTIVE PARTNERS II, L.P.
	 By: Friedman Fleischer & Lowe GP II, LP,
 its general partner

	 By: Friedman Fleischer & Lowe GP II,
 LLC, its general partner

		
	By:	 	 /s/ Spencer Fleischer

	Name:	 	Spencer Fleischer
	Title:	 	Vice Chairman

  

 20

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00096-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00096-of-00352.parquet"}]]